期刊文献+

应用四倍体补偿技术建立血友病A小鼠模型 被引量:5

Generation of factor Ⅷ gene knockout mouse by tetraploid embryo complementation technology
原文传递
导出
摘要 目的建立凝血因子Ⅷ(factorⅧ,FⅧ)基因剔除小鼠模型,为研究治疗血友病A提供理想的动物模型。方法应用ET克隆、胚胎干细胞同源重组和四倍体囊胚补偿技术,将小鼠F阿基因第16~19外显子靶向剔除,并应用PCR、逆转录PCR(reverse transcriptase-PCR,RT-PCR)及免疫组织化学染色技术,从DNA、RNA、蛋白水平检测FⅧ基因的转录及表达情况。通过检测激活的部分凝血活酶时间(activated partial thromboplastin time,APTT)和FⅧ的促凝活性(FⅧ:C)进行FⅧ基因剔除小鼠表型鉴定。结果PCR检测在剔除小鼠中未扩增出FⅧ基因的条带;RT—PCR分析显示剔除区域该基因mRNA转录本缺失;免疫组织化学染色显示在雄性半合子(-/y)和雌性纯合子(-/-)小鼠的肝脏中凝血因子Ⅷ表达缺失;FⅧ:C和APTT检测结果显示雌性杂合子(+/-)FⅧ活性为野生型(wt)的80%,其APTT值较wt略有延长,而-/y和-/-小鼠的FⅧ的活性仅为wt小鼠的8%和10%,且APTT值均大于120s。结论FⅧ基因剔除小鼠具有与人类血友病A患者相似的表型,它的建立将促进我国血友病A治疗新技术的发展。 Objective Factor Ⅷ ( FⅧ) gene knockout mouse model was established for further study on the treatment of hemophilia A. Methods Exons 16-19 of the mouse F Ⅷ gene were knocked out by ET clone, ES homologous recombination and tetraploid embryo compensation technology. PCR, reverse transcriptase-PCR (RT-PCR) and immunohistochemistry were used to detect the transcription and translation pattern of FⅧ. The phenotype of the knockout mice was analyzed by examining the activated partial thromboplastin time (APTT) and FⅧ activity (F Ⅷ: C). Results PCR, RT-PCR and immunohistochemistry confirmed that F Ⅷ was deficient in the F Ⅷ gene knockout mouse. The APTT results showed that F Ⅷ-dcficient mouse plasma had a prolonged clotting time compared to normal mouse plasma. The F Ⅷ : C in heterozygous, hemizygous and homozygous mice was 80%, 8% and 10% of that in normal mice, respectively. Conclusion The phenotype of the F Ⅷ gene knockout mouse appears grossly similar to that of human with hemophilia A. Establishment of this model may promote the development of new technologies of treatment to hemophilia A.
出处 《中华医学遗传学杂志》 CAS CSCD 北大核心 2010年第1期1-6,共6页 Chinese Journal of Medical Genetics
基金 国家自然科学基金(30570971) “十一五”科技支撑计划重大专项(2006BAI23B02) 上海市科委创新团队项目(06DZ05907)
关键词 血友病A 基因剔除 凝血因子Ⅷ 四倍体囊胚补偿技术 hemophilia A gene knockout coagulation factor Ⅷ tetraploid embryo complementation
  • 相关文献

参考文献26

  • 1Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet, 2003, 361:1801- 1809.
  • 2Thompson AR. Structure and function of the factor Ⅷ gene and protein. Semin Thromh Hemost, 2003, 29:11- 22.
  • 3Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype phenotype relationships and inhibitor development. Semin Thromb Hemost, 2003, 29: 23-30.
  • 4Andrikovics H, Klein I, Bors A, et al. Analysis of large structural changes of the factor Ⅷ gene, involving intron 1 and 22, in severe hemophilia A. Haematologica, 2003, 88:778- 784.
  • 5Bagnall RD, Waseem N, Green PM, et al. Recurrent inversion breaking intron 1 of the factor Ⅷ gene is a frequent cause of severe hemophilia A. Blood, 2002, 99;168- 174.
  • 6Nakaya SM, Hsu TC, Geraghty SJ, et al. Severe hemophilia A due to a 1. 3 kb factor Ⅷ gene deletion including exon 24: homologous recombination between 41 bp within an Alu repeat sequence in introns 23 and 24. J Thromb Haemost, 2004, 2: 1941-1945.
  • 7Acquila M, Pasino M, Lanza T, et al. Identification of mutations in exon 14 including five novelties in 13 Italian patients with haemophilia A. Haemophilia, 2004, 10:744-746.
  • 8Rosendaal FR, Smit C, Briet E, et al. Hemophilia treatment in historical perspective: a review of medical and social developments. Arm Hematol, 1991, 62 :5.
  • 9Connelly S, Kaleko M. Gene therapy for hemophilia A. Thromb Haemost, 1997, 78:31.
  • 10Saenko EL, Ananyeva NM, Moayeri M, et al. Development of improved factor Ⅷ molecules and new gene transfer approachesfor hemophilia A. Curr Gene Ther, 2003, 3 :27- 41.

二级参考文献34

  • 1王军平,张友明.Red/ET重组及其在生物医学中的应用[J].生物工程学报,2005,21(3):502-506. 被引量:13
  • 2杨建岭,顾淑萍,陈臣,王铸钢,许燕,费俭,YANG Jian-Ling1, GU Shu-Pir.用Red/ET重组酶构建基因打靶载体[J].生物工程学报,2006,22(6):919-924. 被引量:11
  • 3Liu P, Jenkins NA, Copeland NG. A highly efficient recombineering-based method for generating conditional knockout mutations. Genomie Res, 2003,13: 2190 - 2194
  • 4Zhang Y, Buchholz F, Muyrers JP, Stewart AF. A new logic for DNA engineering using recombination in Escherichia coli. Nature Genet, 1998,20: 123-128
  • 5Muyrers JP, Zhang Y, Buchholz F, Stewart AF. RecE/RecT and Redα/Redβ initiate double-stranded break repair by specifically interacting with their Respective partners. Genes Dev, 2000, 14:1971 - 1982
  • 6Copeland NG, Jenkins NA, Court DL. Reeombineefing: a powerful new tool for mouse functional genomics. Nature Rev Genet, 2001,2:769-779
  • 7Muyrers JP, Zhang Y, Testa G, Stewart AF. Rapid modification of bacterial artificial chromosom-es by ET-recombination. Nucleic Acids Res, 1999, ResplS, pp. 1555- 1557
  • 8Lee EC et al. A highly efficient Escherichia coli-based chromosome engineering system adapted for recom-binogenic targeting and subcloning of BAC DNA. Genomics, 2001, 73: 56-65
  • 9Wach A. PCR-synthesis of marker cassettes with long flanking homology regions for gene disruptions in S. cerevisiae. Yeast, 1996,12: 259-265
  • 10Ulrike Muller. Ten years of gene targeting: targeted mouse mutants,from vector design to phenotype analysis mechanisms of development. 1999, pp.3-21

共引文献11

同被引文献50

  • 1綦凌燕,金春莲,林长坤,任梅红,董文翰,孙开来.F8基因倒位检测及其在甲型血友病基因诊断中的应用[J].中华医学遗传学杂志,2007,24(4):405-408. 被引量:9
  • 2Castaldo G,D'Argenio V,Nardiello P et al.Haemophilia A:molecular insights.Clin Chem Lab Med,2007,45(4):450-461.
  • 3Franchini M.Plasma-derived versus recombinant FactorⅧconcentrates for the treatment of haemophilia A:recombinant is better.Blood Transfus,2010,8(4):292-296.
  • 4Eriksson RK,Fenge C,Lindner-Olsson E et al.The manufacturing process for B-Domain deleted recombinant factorⅧ.Semin Hematol,2001,38(2 Suppl 4):24-31.
  • 5Toole JJ,Knopf JL,Wozney JM et al.Molecular cloning of a cDNA encoding human antihaemophilic factor.Nature,1984,312(5992):342-347.
  • 6Pittman DD,Alderman EM,Tomkinson KN et al.Biochemical,immunological,and in vivo functional characterization of B-Domaindeleted factorⅧ.Blood,1993,81(11):2925-2935.
  • 7Kelley B,Jankowski M,Booth J.An improved manufacturing process for Xyntha/ReFacto AF.Haemophilia,2010,16(5):717-725.
  • 8Rea C,Dunkerley A,Srensen B et al.Pharmacokinetics,coagulation factor consumption and clinical efficacy in patients being switched from full-length FⅧtreatment to B-domain-deleted r-FⅧand back to full-length FⅧ.Haemophilia,2009,15(6):1237-1242.
  • 9Lind P,Larsson K,Spira J et al.Novel forms of B-domain-deleted recombinant factorⅧmolecules Construction and biochemical characterization.Eur J Biochem,1995,232(1):19-27.
  • 10Pastoftp AE,Lykkesfeldt J,Ezban M et al.A sensitive venous bleeding model in haemophilia A mice:effects of two recombinant FⅧproducts(N8 and Advate).Haemophilia,2012,18(5):782-788.

引证文献5

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部